Calamos Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Calamos Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-169,936	Closed	-$31.2M	–	1087
2021 Q2	$31.2M	Buy	169,936 +28,983	+21%	+$4.98M	0.14%	185
2021 Q1	$21.6M	Buy	140,953 +23,325	+20%	+$3.61M	0.12%	195
2020 Q4	$18.4M	Buy	117,628 +8,468	+8%	+$1.09M	0.11%	226
2020 Q3	$12.5M	Sell	109,160 -9,580	-8%	-$1.03M	0.08%	256
2020 Q2	$13.3M	Sell	118,740 -289,115	-71%	-$30.7M	0.09%	239
2020 Q1	$36.6M	Sell	407,855 -276,100	-40%	-$27.1M	0.29%	98
2019 Q4	$74M	Buy	683,955 +102,242	+18%	+$10.9M	0.37%	68
2019 Q3	$57M	Sell	581,713 -67,510	-10%	-$7.61M	0.31%	87
2019 Q2	$85M	Sell	649,223 -38,409	-6%	-$4.95M	0.47%	45
2019 Q1	$93M	Sell	687,632 -46,730	-6%	-$5.81M	0.58%	34
2018 Q4	$71.5M	Buy	734,362 +18,083	+3%	+$2.14M	0.47%	48
2018 Q3	$99.6M	Buy	716,279 +93,533	+15%	+$11.7M	0.55%	34
2018 Q2	$77.3M	Buy	622,746 +27,168	+5%	+$3.18M	0.47%	39
2018 Q1	$66.4M	Buy	595,578 +113,946	+24%	+$13.6M	0.43%	50
2017 Q4	$57.6M	Buy	481,632 +190,921	+66%	+$23.3M	0.29%	59
2017 Q3	$40.8M	Sell	290,711 -43,777	-13%	-$5.95M	0.32%	89
2017 Q2	$40.7M	Buy	334,488 +268,287	+405%	+$31.2M	0.3%	86
2017 Q1	$8.03M	Buy	66,201 +45,119	+214%	+$5.82M	0.06%	303
2016 Q4	$2.58M	Sell	21,082 -256,494	-92%	-$31.4M	0.02%	449
2016 Q3	$34M	Sell	277,576 -217,463	-44%	-$28M	0.24%	135
2016 Q2	$57.8M	Sell	495,039 -34,347	-6%	-$4.87M	0.41%	69
2016 Q1	$73.7M	Buy	529,386 +6,202	+1%	+$911K	0.49%	52
2015 Q4	$99.8M	Buy	523,184 +193,450	+59%	+$33.8M	0.63%	33
2015 Q3	$51.6M	Buy	329,734 +226,350	+219%	+$41.3M	0.36%	85
2015 Q2	$18.7M	Buy	103,384 +82,261	+389%	+$14.2M	0.12%	203
2015 Q1	$3.66M	Sell	21,123 -19,086	-47%	-$3.45M	0.02%	416
2014 Q4	$7.44M	Buy	40,209 +209	+0.5%	+$38.7K	0.05%	305
2014 Q3	$6.63M	Sell	40,000 -1,620	-4%	-$266K	0.04%	303
2014 Q2	$6.5M	Buy	41,620 +21,620	+108%	+$3.41M	0.04%	309
2014 Q1	$3.04M	Sell	20,000 -9,000	-31%	-$1.43M	0.02%	385
2013 Q4	$3.86M	Buy	29,000 +12,000	+71%	+$1.44M	0.02%	350
2013 Q3	$1.98M	Hold	17,000	–	–	0.01%	416
2013 Q2	$1.57M	Buy	+17,000	New	+$1.64M	0.01%	422

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Calamos Advisors's ALXN Position: Q3 2021 in Review

Calamos Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 169,936 shares — an estimated $31.2M sold.

Calamos Advisors first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $99.8M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Calamos Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Calamos Advisors sold 169,936 Alexion Pharmaceuticals shares in Q3 2021, an estimated $31.2M.
Calamos Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Calamos Advisors's Alexion Pharmaceuticals position peaked at $99.8M in Q4 2015.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Calamos Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.